The association between fasting plasma glucose variability and incident eGFR decline: evidence from two cohort studies

Table 2 HRs and 95% CIs of incident eGFR decline ≥ 40% according to each unit increase in FPG variability measures in Tehran Lipid and Glucose Study

Variability measures	Model 1		Model 2		Model 3		Model 4
Variability measures	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
SD
With diabetes	1.00(0.99-1.01)	0.645	0.99 (0.98-1.00)	0.167	0.99 (0.99-1.00)	0.258	0.99 (0.98-1.00)	0.106
Without diabetes	1.08(1.02-1.13)	0.006	1.06(1.01-1.12)	0.020	1.07 (1.01-1.13)	0.012	1.07 (1.01-1.13)	0.014
CV
With diabetes	0.99 (0.98-1.01)	0.511	0.99 (0.97-1.01)	0.158	0.99 (0.97-1.01)	0.190	0.99 (0.97-1.00)	0.138
Without diabetes	1.06(1.01-1.12)	0.012	1.05 (1.00-1.11)	0.033	1.06 (1.01-1.11)	0.017	1.06 (1.01-1.11)	0.017
ARV
With diabetes	1.00(0.99-1.01)	0.874	1.00 (0.99-1.00)	0.310	1.00 (0.99-1.00)	0.513	1.00 (0.99-1.00)	0.309
Without diabetes	1.03(0.99-1.07)	0.158	1.03(0.99-1.07)	0.137	1.03 (0.99-1.07)	0.183	1.03 (0.99-1.07)	0.208
VIM
With diabetes	1.00 (0.98-1.01)	0.463	0.99 (0.98-1,00)	0.252	0.99 (0.98-1.00)	0.233	0.99 (0.98-1.00)	0.250
Without diabetes	1.07(1.01-1.13)	0.016	1.06 (1.00-1.11)	0.041	1.07 (1.01-1.13)	0.019	1.07 (1.01-1.13)	0.018

Model 1: adjusted for age and sex at baseline (phase 2)
Model 2: Model 1 + marital status, education, ever smoking, prevalent CVD, physical activity, anti-diabetic drug use, anti-hypertensive drug, lipid-lowering drug, BMI, WC, SBP, DBP, eGFR, and FPG at baseline (phase 2)
Model 3: Model 1 + marital status, education, ever smoking, prevalent CVD, and physical activity at baseline (phase 2), and anti-diabetic drug use, anti-hypertensive drug, and lipid-lowering drug over phases 2–4, and average BMI, WC, SBP, DBP, and eGFR over phases 2–4
Model 4: Model 3 + average FPG

ISSN: 1471-2458